CDK8 Regulation Of Lipid Metabolism | 6469
ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

CDK8 regulation of lipid metabolism

International Conference and Exhibition on Obesity & Weight Management

Fajun Yang

Accepted Abstracts: J Obes Wt Loss Ther

DOI: 10.4172/2165-7904.S1.006

Transcriptional cofactors play pivotal roles in the precise control of gene expression, and thus are involved in human health problems, including obesity. The multi-subunit protein complex named Mediator is a transcriptional cofactor, which can bridge transcription factors to the basal transcription apparatus. Cyclin-dependent kinase-8 (CDK8) is a subunit of the Mediator complex. However, the biological functions of CDK8 remain poorly understood. Here, we identify CDK8 as a negative regulator of lipogenic gene expression by suppressing the SREBP-1c transcription factor, which is a key activator of rate-limiting enzymes in the de novo lipogenesis pathway. CDK8 knockdown in hepatocytes results in SREBP-dependent up-regulation of lipogenic genes and an increase of lipid accumulation. Transient knockdown of CDK8 in mouse liver in vivo leads to increased expression of SREBP-target genes. As a result, hepatic CDK8 knockdown causes acceleration of de novo lipogenesis and accumulation of neutral lipids in mouse liver. In addition, hepatic CDK8 knockdown in mice results in an increase of plasma triglycerides. Consistent with the inhibitory role of CDK8 in de novo lipogenesis, hepatic CDK8 proteins in mouse models of obesity are significantly lower than normal. Dysregulation of lipid metabolism in obesity causes fatty liver and dyslipidemia, which are prevalent health problems in the developed countries and are closely associated with type II diabetes and cardiovascular disease. Thus, CDK8 may play a role in the development of fatty liver and dyslipidemia in obesity.